News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Aug 8, 2019

    SAN DIEGO, August 8, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Aug 8, 2019
    NDA for PF708 reached the FDA mid-cycle review milestone in May | Positive Phase 1 results for PF743 (JZP-458) and Jazz advances the product to Pivotal Phase 2/3 Study | Agreement with Arcellx Leverages Pfēnex Expression Technology® platform

    SAN DIEGO, August 8, 2019 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Aug 1, 2019
    First Arcellx sparX protein successfully completed process development using Pfēnex Expression Technology® platform | Second sparX program initiated by Arcellx

    SAN DIEGO, August 1, 2019 —Pfenex Inc. (NYSE American: PFNX) and Arcellx, Inc. today announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfe

  • Jul 25, 2019

    SAN DIEGO, July 25, 2019-- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...

  • Jun 5, 2019

    SAN DIEGO, June 5, 2019 —Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...

Show 5102550100 per page